Nexag (Tranexamic Acid)

Tranexamic Acid, the active ingredient in Nexag, is an antifibrinolytic presented as an oral formulation for systemic use. It helps reduce excessive bleeding in conditions such as heavy menstrual bleeding, trauma‑related bleeding and surgical bleeding.

GNH USA supplies Nexag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nexag, an antifibrinolytic, is employed to control bleeding in several clinical settings.

- Heavy menstrual bleeding: reduces menstrual blood loss and improves quality of life. - Trauma‑related bleeding: stabilises clot formation after injury to limit blood loss. - Surgical bleeding: minimizes intra‑operative and post‑operative hemorrhage, supporting faster recovery.

Tranexamic acid is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools occurring during treatment. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Thromboembolic events: formation of clots in veins or arteries. - Hypersensitivity reactions: rash, itching, or anaphylaxis. - Visual disturbances: blurred vision or retinal changes. - Renal impairment: reduced kidney function in susceptible patients.

Before prescribing Nexag, clinicians should consider several safety measures.

- Assess bleeding risk: evaluate patient history for coagulopathies. - Monitor renal function: adjust use in patients with impaired kidneys. - Review concomitant anticoagulants: avoid additive bleeding risk. - Use with caution in thrombosis history: consider alternative therapy. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep in original pack, protect from moisture.

Tranexamic acid may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Procoagulant agents (e.g., activated factor VII): may increase clotting risk. - Combined use with other antifibrinolytics (e.g., aprotinin): excessive inhibition of fibrinolysis. - Hormonal contraceptives containing estrogen: heightened thrombosis potential.

Moderate Interactions (Monitor Closely): - NSAIDs: may counteract hemostatic benefit. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding. - Warfarin: possible alteration of INR values. - SSRIs or SNRIs: increased bleeding tendency, require observation.